169 related articles for article (PubMed ID: 31133447)
41. Sclerotherapy for vascular malformations: complications and a review of techniques to avoid them.
Odeyinde SO; Kangesu L; Badran M
J Plast Reconstr Aesthet Surg; 2013 Feb; 66(2):215-23. PubMed ID: 23059134
[TBL] [Abstract][Full Text] [Related]
42. Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations.
Jin Y; Lin X; Li W; Hu X; Ma G; Wang W
J Vasc Surg; 2008 Jun; 47(6):1292-9. PubMed ID: 18387776
[TBL] [Abstract][Full Text] [Related]
43. Severe Edema After Sclerotherapy of Labial Hemangioma With Ethamolin Oleate in a Young Child.
de Queiroz SB; de Lima VN; Amorim PH; Statkievicz C; Magro-Filho O
J Craniofac Surg; 2016 Sep; 27(6):e567-8. PubMed ID: 27428925
[TBL] [Abstract][Full Text] [Related]
44. Albumin inhibits hemolysis of erythrocytes induced by ethanolamine oleate during endoscopic injection sclerotherapy.
Ohta M; Hashizume M; Ueno K; Tanoue K; Sugimachi K
Hepatogastroenterology; 1993 Feb; 40(1):65-8. PubMed ID: 8462932
[TBL] [Abstract][Full Text] [Related]
45. Arteriovenous malformations: ethanolamine oleate sclerotherapy.
Hyodoh H; Hyodoh K
Acta Chir Iugosl; 2007; 54(3):81-6. PubMed ID: 17988037
[TBL] [Abstract][Full Text] [Related]
46. Preoperative sclerotherapy of facial venous malformations: impact on surgical parameters and long-term follow-up.
James CA; Braswell LE; Wright LB; Roberson PK; Moore MB; Waner M; Buckmiller LM
J Vasc Interv Radiol; 2011 Jul; 22(7):953-60. PubMed ID: 21550819
[TBL] [Abstract][Full Text] [Related]
47. Haptoglobin prevents renal dysfunction associated with intravariceal infusion of ethanolamine oleate.
Miyoshi H; Ohshiba S; Matsumoto A; Takada K; Umegaki E; Hirata I
Am J Gastroenterol; 1991 Nov; 86(11):1638-41. PubMed ID: 1951242
[TBL] [Abstract][Full Text] [Related]
48. Comparative outcomes for sclerotherapy of head and neck venous vascular malformation between alcohol and bleomycin.
Songsaeng D; Churojana A; Khumthong R; Mahiwan L
J Med Assoc Thai; 2015 Apr; 98(4):408-13. PubMed ID: 25958717
[TBL] [Abstract][Full Text] [Related]
49. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy.
Spence J; Krings T; TerBrugge KG; Agid R
Head Neck; 2011 Jan; 33(1):125-30. PubMed ID: 20848431
[TBL] [Abstract][Full Text] [Related]
50. Real-time MRI-guided percutaneous sclerotherapy treatment of venous low-flow malformations in the head and neck.
Partovi S; Lu Z; Vidal L; Nakamoto DA; Buethe J; Coffey M; Patel IJ
Phlebology; 2018 Jun; 33(5):344-352. PubMed ID: 28516809
[TBL] [Abstract][Full Text] [Related]
51. Treatment of esophageal varices: low versus high dose of 5% ethanolamine oleate.
Neeman A; Leiser A; Kadish U
Am J Gastroenterol; 1991 Sep; 86(9):1182-4. PubMed ID: 1882797
[TBL] [Abstract][Full Text] [Related]
52. Complications of sclerotherapy for 75 head and neck venous malformations.
Castrén E; Aronniemi J; Klockars T; Pekkola J; Lappalainen K; Vuola P; Salminen P; Pitkäranta A
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1027-36. PubMed ID: 25731642
[TBL] [Abstract][Full Text] [Related]
53. Standard guidelines for care: sclerotherapy in dermatology.
Khunger N; Sacchidanand S
Indian J Dermatol Venereol Leprol; 2011; 77(2):222-31. PubMed ID: 21393966
[TBL] [Abstract][Full Text] [Related]
54. High-flow arteriovenous malformation of the lower extremity: ethanolamine oleate sclerotherapy.
Hyodoh H; Fujita A; Hyodoh K; Furuse M; Kamisawa O; Hareyama M
Cardiovasc Intervent Radiol; 2001; 24(5):348-51. PubMed ID: 11815844
[TBL] [Abstract][Full Text] [Related]
55. Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations.
Dompmartin A; Blaizot X; Théron J; Hammer F; Chene Y; Labbé D; Barrellier MT; Gaillard C; Leroyer R; Chedru V; Ollivier C; Vikkula M; Boon LM
Eur Radiol; 2011 Dec; 21(12):2647-56. PubMed ID: 21822948
[TBL] [Abstract][Full Text] [Related]
56. Ethanolamine oleate: a dangerous and outmoded sclerosant.
Duffy DM
Dermatol Surg; 2011 Mar; 37(3):402. PubMed ID: 21410823
[No Abstract] [Full Text] [Related]
57. Bevacizumab and interferon reduce venous recanalization following sclerotherapy.
Kulungowski AM; Hassanein AH; Foster CC; Greene AK; Fishman SJ
J Pediatr Surg; 2016 Oct; 51(10):1670-3. PubMed ID: 27570240
[TBL] [Abstract][Full Text] [Related]
58. Retrospective analysis of facial paralysis caused by ethanol sclerotherapy for facial venous malformation.
Hu X; Chen D; Jiang C; Jin Y; Chen H; Ma G; Lin X
Head Neck; 2011 Nov; 33(11):1616-21. PubMed ID: 21990226
[TBL] [Abstract][Full Text] [Related]
59. Sclerotherapy of benign oral vascular lesion with ethanolamine oleate: an open clinical trial with 30 lesions.
Johann AC; Aguiar MC; do Carmo MA; Gomez RS; Castro WH; Mesquita RA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Nov; 100(5):579-84. PubMed ID: 16243243
[TBL] [Abstract][Full Text] [Related]
60. Sclerotherapy for vascular malformations in the oral and maxillofacial region: treatment and follow-up of 66 lesions.
Costa JR; Torriani MA; Hosni ES; D'Avila OP; de Figueiredo PJ
J Oral Maxillofac Surg; 2011 Jun; 69(6):e88-92. PubMed ID: 21272976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
